Anand Bhaskar — SEC insider filings

SEC reporting owner CIK 1890784. 18 insider filings on record with FilingPulse; latest filed 2026-10-14.

Transaction summary — filings shown

Covers all 18 filings on record, filed 2022-01-05 to 2026-10-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
REATA PHARMACEUTICALS INC (RETA)SVP, Chief Accounting Officer10—8 legs · 5,223 sh · $554,33413
Summit Therapeutics Inc. (SMMT)Chief Accounting Officer8——9

Insider filings — Anand Bhaskar

FiledFormIssuerReported transactionsSource
2026-10-144Summit Therapeutics Inc. (SMMT)Grant/award (A): 100,000 @ $0EDGAR
2026-01-124Summit Therapeutics Inc. (SMMT)Grant/award (A): 30,000 (derivative)EDGAR
2025-10-234Summit Therapeutics Inc. (SMMT)Grant/award (A): 26,680 @ $18.74EDGAR
2025-09-194Summit Therapeutics Inc. (SMMT)Grant/award (A): 50,000 (derivative)EDGAR
2025-05-014Summit Therapeutics Inc. (SMMT)Grant/award (A): 600,000 (derivative) · Grant/award (A): 75,000 (derivative)EDGAR
2025-01-144Summit Therapeutics Inc. (SMMT)Grant/award (A): 75,000 (derivative)EDGAR
2024-09-134Summit Therapeutics Inc. (SMMT)Grant/award (A): 22,026 @ $22.70EDGAR
2024-04-044Summit Therapeutics Inc. (SMMT)Grant/award (A): 600,000 (derivative)EDGAR
2023-09-264REATA PHARMACEUTICALS INC (RETA)Disposition to issuer (D): 24,089 · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 23,438 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 33,500 (derivative)EDGAR
2023-09-074REATA PHARMACEUTICALS INC (RETA)Sale (S): 406 @ $169.20EDGAR
2023-08-174REATA PHARMACEUTICALS INC (RETA)Sale (S): 193 @ $169.06 · Sale (S): 210 @ $168.42EDGAR
2023-06-164REATA PHARMACEUTICALS INC (RETA)Option exercise (M): 1,562 @ $27.32 · Sale (S): 2,343 @ $102.11 · Option exercise (M): 1,562 (derivative) @ $0EDGAR
2023-05-174REATA PHARMACEUTICALS INC (RETA)Sale (S): 950 @ $85.98 · Sale (S): 136 @ $81.10EDGAR
2023-03-084REATA PHARMACEUTICALS INC (RETA)Sale (S): 165 @ $84.58EDGAR
2023-03-064REATA PHARMACEUTICALS INC (RETA)Sale (S): 820 @ $87.47EDGAR
2023-03-024REATA PHARMACEUTICALS INC (RETA)Grant/award (A): 3,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0EDGAR
2023-01-044REATA PHARMACEUTICALS INC (RETA)Grant/award (A): 8,250 @ $0 · Grant/award (A): 33,500 (derivative) @ $0EDGAR
2022-01-054REATA PHARMACEUTICALS INC (RETA)Grant/award (A): 12,500 @ $0 · Grant/award (A): 25,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2022-01-03 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1890784 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs